Pearl Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2006-01-01
- Employees
- 51
- Market Cap
- -
Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: GFF MDI (PT003)Drug: FF MDI (PT005)Drug: PlaceboDrug: GP MDI (PT001)
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 1615
- Registration Number
- NCT01854658
- Locations
- 🇺🇸
Pearl Investigative Siteq, Baltimore, Maryland, United States
🇺🇸Pearl Investigative Site, Bridgeport, West Virginia, United States
Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2012-04-27
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 159
- Registration Number
- NCT01587079
- Locations
- 🇺🇸
Pearl Investigative Site, Morgantown, West Virginia, United States
PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT01566773
- Locations
- 🇺🇸
Pearl Investigative Site, Richmond, Virginia, United States
PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2011-05-09
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT01350128
- Locations
- 🇺🇸
Pearl Investigative Site, Richmond, Virginia, United States
PT003 MDI Dose Confirmation Study
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2011-05-09
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 185
- Registration Number
- NCT01349816
- Locations
- 🇺🇸
Pearl Investigative Site, Spartanburg, South Carolina, United States
PT005 MDI Dose Ranging Versus Foradil Aerolizer Study
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: PT005 MDIOther: Placebo MDI
- First Posted Date
- 2011-05-09
- Last Posted Date
- 2012-09-12
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT01349868
- Locations
- 🇺🇸
Pearl Investigative Site, Spartanburg, South Carolina, United States
PT003 MDI Cardiovascular Safety Study
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2011-05-09
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 237
- Registration Number
- NCT01349803
- Locations
- 🇳🇿
Pearl Investigative Site, Newtown, Wellington, New Zealand
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: PT003 MDIDrug: Placebo MDIDrug: PT001 MDIDrug: PT005 MDI
- First Posted Date
- 2010-03-11
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 118
- Registration Number
- NCT01085045
- Locations
- 🇺🇸
Clinical Research Institute of Southern Oregon, PC, Medford, Oregon, United States
🇺🇸Spartanburg Medical Research, Spartanburg, South Carolina, United States
🇦🇺Respiratory Research Foundation - Burnside War Memorial Hospital, Adelaide, South Australia, Australia
Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control
Phase 2
Withdrawn
- Conditions
- COPD
- Interventions
- First Posted Date
- 2010-01-07
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Registration Number
- NCT01043601
- Locations
- 🇺🇸
Spartanburg Medical Research, Spartanburg, South Carolina, United States
Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2009-05-06
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT00893971
- Locations
- 🇦🇺
Dr Joanne Marjason, Herston, Queensland, Australia
© Copyright 2025. All Rights Reserved by MedPath